Beasley Allen lawyer Andy Birchfield, who heads up the firm’s Mass Torts section handling cases involving dangerous drugs and medical devices, recently provided Law360 with his thoughts on Plaintiffs law. Law360 is an online resource of comprehensive legal news, covering litigation, policy developments, and other topics spanning a variety of practice areas, industries and jurisdictions.
In a column titled “Plaintiffs Bar Perspective,” Andy says representing a plaintiff versus representing a defendant is the difference between an “intensely personal” experience on the part of the plaintiff, versus a matter that is largely business on the defendant’s side. He says he views his work as a ministry, to guide clients through life-altering events in what is often the most difficult time in their life.
“We know we will not be able to reverse the injuries our clients suffered or replace the family members they lost, but sometimes we can help ease their financial burdens and hold the wrongdoers accountable,” Andy tells Law360.
After joining Beasley Allen in 1996, Andy handled cases involving consumer fraud and commercial litigation. He later proved to be instrumental in developing the Mass Torts Litigation Section in 2000, which now consists of 35 lawyers and 85 support staff.
Andy headed the firm’s Vioxx litigation and served as co-lead counsel for the Plaintiffs Steering Committee (PSC) for the Vioxx multidistrict litigation (MDL). That litigation resulted in a $4.85 billion global settlement. He was most recently a leader in the Actos litigation, helping to secure a $2.4 billion settlement. He is currently serving as co-lead counsel in the Xarelto MDL, with claims related to serious bleeding risks associated with the blood-thinning drug.
To read the full interview with Andy, visit Law360 online.